您当前的位置:
首页 >
文章列表页 >
Targeting BMI1 mitigates chemoresistance in ovarian cancer
更新时间:2022-11-09
    • Targeting BMI1 mitigates chemoresistance in ovarian cancer

    • Genes & Diseases   Vol. 9, Issue 6, (2022)
    • 作者机构:

      1. Department of Obstetrics and Gynecology, University of Oklahoma Health Science Center,OK,Oklahoma City,USA,73104

      2. Department of Aging and Metabolism Research Program, Oklahoma Medical Research Foundation,OK,Oklahoma City,USA,73104

      3. Department of Pathology, University of Oklahoma Health Science Center,OK,Oklahoma City,USA,73104

      4. Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, California Northstate University, Elk Grove,CA,USA,95757

      5. Department of Cell Biology, University of Oklahoma Health Science Center,OK,Oklahoma City,USA,73104

      6. Peggy and Charles Stephenson Cancer Center, University of Oklahoma Health Science Center,OK,Oklahoma City,USA,73104

      7. PTC Therapeutics, Inc, South Plainfield,NJ,USA,07080

    • DOI:10.1016/j.gendis.2022.02.006    

      CLC:
    • Published:2022,

      Published Online:1 November 2022,

    扫 描 看 全 文

  • Anindya Dey, Shailendra Kumar Dhar Dwivedi, Lin Wang, et al. Targeting BMI1 mitigates chemoresistance in ovarian cancer. [J]. Genes & Diseases 9(6).(2022) DOI: 10.1016/j.gendis.2022.02.006.

  •  
  •  
查看原文

0

Views

0

下载量

0

CSCD

Alert me when the article has been cited
提交
Tools
Download
Export Citation
Share
Add to favorites
Add to my album

Related Articles

No data

Related Author

No data

Related Institution

No data
0